Abstract
Dendritic cells (DC) constitute a family of antigen-presenting cells defined by their morphology and their unique capacity to initiate a primary immune response [1]. It has been shown that DC pulsed with MHC class I peptides are potent inducers of a cytotoxic T lymphocyte (CTL) response in vitro [2]. Furthermore, the presence of DC in tumor tissue has been correlated with a favorable clinical prognosis. Therefore DC are thought to play a pivotal role in the induction of T cell-mediated anti-tumor responses in vivo [3–5]. We, and several other laboratories in the world have initiated clinical studies in which DC vaccines are used to treat cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bakker, A.B, Schreurs, MW, Tafazzul, G et al. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2. 1-restricted anti-melanoma CTL line. Int J Cancer 1995;62:97–102.
Celis, E, Tsai, V, Crimi, C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105–09.
Banchereau, J and Steinman, R M. Dendritic cells and the control of immunity. Nature 1998;392:245–52.
Hart, DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245–87.
Lanzavecchia, A. and Sallusto, F. Regulation of T cell immunity by dendritic cells. Cell 2001;106:263–66.
De Vries, IJ, Eggert, AA, Scharenborg, NM, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002; 25:429–38.
Romani, N, Gruner, S, Brang, D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83–93.
Van den Eynde, BJ and van der Bruggen, P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684–93.
Hsu, FJ, Benike, C, Fagnoni, F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2: 52–58.
Nestle, FO, Alijagic, S, Gilliet, M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–32.
Thurner, B, Haendle, I, Roder, C, et al. Vaccination with mage-3A1 peptidepulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669–78.
Nestle, FO., Banchereau, J, Hart, D. Dendritic cells: On the move from bench to bedside. Nat Med 2001;7:761–65.
Brichard, V, Van Pel, A, Wolfel, T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489–95.
Parlato, S, Santini, SM, Lapenta, C et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 2001;98:3022–29.
Takayama, T, Morelli, AE, Onai, N, et al. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J. Immunol. 2001;166:7136–43.
De Vries, IJM, Krooshoop, DJEB, Scharenborg, NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003 (in press).
Kukutsch, NA, Rossner, S, Austyn, JM, Schuler, G, Lutz, MB. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J. Invest. Dermatol. 2000;115:449–53.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media Dordrecht
About this paper
Cite this paper
de Vries, J., Adema, G.J., Punt, C.J.A., Figdor, C.G. (2003). State of the Art in Dendritic Cell Vaccination. In: Sibinga, C.T.S., De Leij, L.F.M.H. (eds) Cellular Engineering and Cellular Therapies. Developments in Hematology and Immunology, vol 38. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3718-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3718-9_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5250-9
Online ISBN: 978-1-4757-3718-9
eBook Packages: Springer Book Archive